持续VA化疗与中大剂量阿糖胞苷巩固治疗在适合标准化疗的急性髓系白血病缓解后治疗中的疗效比较
该回顾性研究纳入河北医科大学第二医院经VA方案诱导后转为适合标准化疗的AML患者69例,比较持续VA化疗(46例)与I/HDAC巩固(23例)的疗效与安全性。两组中位OS、RFS、EFS差异均无统计学意义,但I/HDAC组在ELN低危、MRD阳性、FLT3野生型及IDH1/2突变亚组中位OS较VA组延长,VA组3~4级粒细胞减少、血小板减少及血流感染发生率显著更低。
要点
- VA组与I/HDAC组中位OS、RFS、EFS差异均无统计学意义(P值均>0.05)。
- ELN低危、MRD阳性、FLT3野生型或IDH1/2突变患者接受I/HDAC巩固中位OS较VA组延长(P<0.05)。
- VA组3~4级粒细胞减少、3~4级血小板减少及血流感染发生率显著低于I/HDAC组(P<0.05)。
核心结论
- 对于ELN低危、MRD阳性、FLT3野生型或IDH1/2突变的缓解后适合标准化疗状态AML患者,接受I/HDAC巩固强化化疗可能较持续VA化疗OS期延长。
- 缓解后VA持续化疗安全性优于I/HDAC巩固强化化疗。
研究设计与样本
- 回顾性分析2020年8月至2024年1月在河北医科大学第二医院血液科经VA方案诱导治疗后适合标准化疗状态患者的缓解后治疗临床资料。
- 共纳入69例患者,VA方案持续治疗组46例,I/HDAC巩固强化化疗组23例。
主要发现
- VA组中位OS、RFS、EFS分别为26.18、24.69、20.34个月,I/HDAC组分别为34.14、30.99、28.42个月,差异均无统计学意义(P值均>0.05)。
- I/HDAC组中ELN低危、MRD阳性、FLT3野生型和IDH1/2突变亚组的中位OS期较VA组中相应亚组延长(P值均<0.05)。
- VA组3~4级粒细胞减少、3~4级血小板减少及血流感染发生率显著低于I/HDAC组(P值均<0.05)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective: To compare the efficacy and safety of continuous venetoclax combined azacitidine (VA) chemotherapy and intermedium/high-dose cytarabine (I/HDAC) consolidation in patients with acute myeloid leukemia (AML) fit for standard chemotherapy (transform from UNFIT) . Methods: Clinical data of patients who were fit for standard chemotherapy were collected among those with AML who underwent VA induction in the Department of Hematology, the Second Hospital of Hebei Medical University. The overall survival (OS), relapse-free survival (RFS), event-free survival (EFS), and incidence of adverse events were analyzed retrospectively. Results: This study enrolled 69 patients, consisting of 46 cases in the VA group and 23 cases in the I/HDAC group. We revealed the following. ① The median OS, RFS, EFS were 26.18, 24.69, 20.34 months in the VA group, and 34.14, 30.99, 28.42 months in the I/HDAC group, respectively, with no statistically significant difference (all P>0.05). Median OS of patients who underwent I/HDAC consolidation with European Leukemia Net (ELN) favorable-risk, positive measurable residual disease (MRD), wild type FLT3, or IDH1/2 mutation was significantly longer than those who received VA (P<0.05). ②Adverse events rate of grade 3 - 4 neutropenia, grade 3 - 4 thrombocytopenia, and bacteremia were significantly lower in the VA group than in the I/HDAC group (P<0.05) . Conclusions: I/HDAC consolidation was more likely to help get survival benefits for patients with ELN favorable-risk, positive MRD, wild type FLT3, or IDH1/2 mutation. Continuous VA chemotherapy exhibited superior safety than I/HDAC consolidation. 目的: 比较维奈克拉联合阿扎胞苷(VA)持续化疗和中大剂量阿糖胞苷(I/HDAC)巩固强化治疗对缓解后转FIT(Fit for standard chemotherapy)状态急性髓系白血病(AML)的疗效及安全性。 方法: 收集2020年8月至2024年1月在河北医科大学第二医院血液科经VA方案诱导治疗后FIT状态患者的缓解后治疗临床资料,回顾性分析VA持续化疗和I/HDAC治疗方案疗效差异,观察指标包括总生存(OS)期、无复发生存(RFS)期、无事件生存(EFS)期,以及化疗相关不良反应发生率。 结果: 共收集69例患者资料,其中VA方案持续治疗组46例,I/HDAC巩固强化化疗组23例。VA组中位OS、RFS、EFS期分别为26.18、24.69、20.34个月,I/HDAC组分别为34.14、30.99、28.42个月,差异均无统计学意义(P值均>0.05)。I/HDAC组中欧洲白血病网(ELN)低危、微小残留病(MRD)阳性、FLT3野生型和IDH1/2突变亚组的中位OS期较VA组中相应亚组延长(P值均<0.05)。VA组3~4级粒细胞减少、3~4级血小板减少及血流感染发生率显著低于I/HDAC组(P值均<0.05)。 结论: 对于ELN低危、MRD阳性、FLT3野生型或IDH1/2突变的缓解后FIT状态AML患者,接受I/HDAC巩固强化化疗可能较持续VA化疗OS期延长。缓解后VA持续化疗安全性优于I/HDAC巩固强化化疗。.
引用
- Sun L, Zhang PP, Ren SM, et al. [Comparison of the efficacy of continuous VA chemotherapy and I/HDAC consolidation in postremission therapy for acute myeloid leukemia fit for standard chemotherapy]. Zhonghua Xue Ye Xue Za Zhi. 2025. PMID: 40425456. doi:10.3760/cma.j.cn121090-20240529-00198
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。